Roche’s Tecentriq has been shown to improve survival in non-small cell lung cancer (NSCLC) patients who are not eligible for platinum-based doublet chemotherapy, according to data from the Phase III IPSOS trial. The study, led by University College London (UCL) and supported by Roche, revealed its findings in The Lancet. The results showed that patients treated with Tecentriq had a median overal..
Celldex Therapeutics, Inc. has initiated their Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE) with the dosing of the first patient. EoE is a chronic inflammatory disease that affects the esophagus and is the most common form of eosinophilic gastrointestinal disease. The objective of this study is to assess the effectiveness and safety of subcutaneous barzolvolimab in patients w..
Scientific Officer of Biodexa Pharmaceuticals PLC, expressed his satisfaction with the study's results. He emphasized that the study provided valuable insights into the safety and efficacy of intra-tumoral administration of MTX110 via CED. The success of this study has led to a follow-up Phase I study at Columbia University.
Secarna Pharmaceuticals, a biopharmaceutical company specializing in antisense oligonucleotide (ASO) therapies, has published new preclinical data in The Journal of Immunology. The data demonstrates the potent therapeutic activity of their LNAplus(TM) ASO targeting NLRP3 in debilitating autoinflammatory diseases. NLRP3 is a central component of the inflammasome pathway, which is overactive in ma..
Curis, Inc., a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. The recommended phase 2 dose (RP2D) f..
